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Abstract
Background:  Pseudomyxoma peritonei (PMP) is a rare, chronic, relapsing, diagnostically
challenging and poorly understood disease characterized by disseminated mucinous ascites and
peritoneal implants.
Case presentation: We report two cases of PMP that represent the two biological variants of
disseminated  peritoneal  adenomucinosis (DPAM) – the benign variant and the peritoneal
mucinous carcinomatosis (PMCA) – the malignant variant, both of which were characterized by
multiple relapses and progression of the disease despite aggressive management.
Conclusion: Even with a better understanding and recent advances in the management of these
cases, PMP remains an enigmatic disease with a protracted clinical course characterized by multiple
recurrences despite surgery and/or chemotherapy. Recognition of PMP as a delayed consequence
years later should alert all surgeons to be extremely vigilant when treating mucinous neoplasms of
the appendix, with special care being directed towards adequate excision and thorough
debridement at the initial diagnosis.
Background
Pseudomyxoma peritonei (PMP) first described by Werth
[1] is an uncommon and poorly understood disease char-
acterized by abundant extracellular mucin in the perito-
neum. The "myxomatous" appearance is attributed to the
associated fibroblastic and vascular proliferation that is
probably incited by the mucin. This results in multifocal
peritoneal, serosal and ommental implants admixed with
copious amounts of mucin accumulation within the
abdomen and pelvis resulting in the belly full of jelly –
"the jelly belly" [2]. PMP is a broad descriptive term
embracing a wide spectrum of biological behavior of neo-
plasms from the benign to the borderline to the frankly
malignant lesion. Other terminologies to reflect this spec-
trum of biological behavior ranges from disseminated
peritoneal adenomucinosis (DPAM) – the benign variant
to  peritoneal  mucinous  carcinomatosis (PMCA) – the
malignant variant [3]. A definitive diagnosis of PMP
requires the presence of a) mucinous neoplastic cells/epi-
thelium, and b) mucinous ascites – diffuse intraabdomi-
nal mucin. Some authors also require the presence of
diffuse mucinous implants for this diagnosis. Viable epi-
thelial glandular cells must be identified within the mucin
pools by histological analysis to diagnose PMP. Cases
without epithelium are regarded as mucinous ascites.
Pseudomyxoma peritonei (PMP) is more commonly seen
in women [4] who usually present with increasing
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abdominal girth and this tends to be related to an under-
lying ovarian lesions which are usually mucinous tumors
that can be associated with a teratoma. Though uncom-
mon in men, these cases are virtually all associated with a
lesion in the appendix [5]. Other possible primary sites
include colorectum, gallbladder, pancreas, urachus, uri-
nary bladder, breast and lung [6], but these are uncom-
mon. These primary sites are usually associated with the
malignant variant-PMCA of PMP. PMP can occur years
(range from 5–35 years) later after the initial presentation
of an appendiceal event [7] and, therefore, accurate diag-
nosis prior to surgery is often delayed and inaccurate. The
disease may be localized in the right lower quadrant ini-
tially and then become more generalized with mucinous
peritoneal, serosal and ommental implants. There is
increasing recognition that the two variants DPAM and
PMCA are different with the DPAM remaining localized to
the abdomen without metastatic behavior and the PCMA
behaving like a mucinous (colloid) carcinoma with meta-
static and invasive potential. 10% of patients die of PMP
within 5.5 years of their initial presentation while others
experience recurrent and/or residual disease. Advanced
abdominal disease leading to intestinal obstruction
accounts for majority of the patients' morbidity and mor-
tality. We report two cases of delayed PMP in men associ-
ated with appendiceal lesions with a long latent period in
one case. Although both underwent surgery and one had
adjuvant chemotherapy, a protracted clinical course with
chronicity and relapse of the disease was a common fea-
ture.
Case presentation
Case 1 This is a 42 years old male with a history of a rup-
tured appendiceal mucinous neoplasm that was removed
23 years ago. He was asymptomatic until the fall of 1999
when he started complaining of recurrent small bowel
obstruction and weight loss. He had undergone multiple
investigations and was thought to have underlying
Crohn's disease. A computed tomographic (CT) scan of
his abdomen in January 2000 demonstrated a large
abdominal mass. A laparoscopy was performed for tissue
diagnosis of a possible lymphoma. However, at the time
of laparoscopy, a large gelatinous mass was found and the
diagnosis of PMP was confirmed by histopathology.
Debulking surgery with small bowel resections was per-
formed following this diagnosis at the Royal University
Hospital of Saskatchewan. Since then he remained well
and was reviewed regularly in the outpatient clinic. Four
years later (2003), the patient began experiencing obstruc-
tive symptoms again due to recurrent disease and he had
a further extensive debulking surgery in January 2004.
This was followed a year later by another cytoreductive
surgery with small bowel resection in 2005. He is cur-
rently doing well at a 3 months post-operative follow-up
visit.
Pathology findings
The specimens from 2000 consisted of a portion of small
bowel with several gelatinous, "mucinous" masses
attached to the peritoneal surface of the serosa of the
bowel wall accompanied by the presence of lobulated
polypoid gelatinous tissue (Figure 1a). The specimens
from 2004 and 2005 had a similar gross appearance. His-
tologically, however, the tumor showed significant pro-
gression over the years from a predominantly
hypocellular, benign looking single layer of bland epithe-
lium in extracellular pools of mucin in year 2000 (Figure
1b) to a mild increase in epithelial proliferation in 2004
to a hypercellular lesion associated with cytological atypia
and numerous free "cell clusters" floating in the extracel-
lular mucin pools and infiltrating the submucosa of the
small bowel (Figure 1c) representing the PMCA variant
with a documented past history of ruptured appendiceal
mucinous neoplasm 23 years ago with no material availa-
ble for current pathological review.
Case 2 This was a 63-year-old male who presented with
fatigue and dyspnea in the spring of 1995. He was investi-
gated for his anemia and found by ultrasound to have
multiple cystic structures within the peritoneal cavity. The
CT scan confirmed the presence of multiple peritoneal
masses associated with a large amount of intra-abdominal
ascites (Figure 2a). At laparoscopy the abdominal cavity
was filled with mucin. Biopsy and histopathological
examination of the peritoneal mass confirmed the pres-
ence of PMP. Cytoreductive surgery inclusive of a right
hemicolectomy was performed, followed by intra-perito-
neal chemotherapy. The patient had been doing well for 4
years. Then, he complained of increased abdominal girth
and coughing, and a CT scan showed recurrence of exten-
sive amount of multiloculated material throughout the
abdomen and pelvis. Therefore, the second debulking sur-
gery was performed on September 1999. The patient
made an uneventful recovery and was discharged in a sta-
ble condition. In June 2002, he had the third debulking
surgery for recurrent disease. In February 2003 he died
from a myocardial infarction – an unrelated cause.
Pathology findings
The gross appearance of the PMP was similar to the previ-
ously described case. A diagnosis of PMP originating from
a mucinous neoplasm of low malignant potential (M-
LMP) originating in the appendix from the hemicolec-
tomy specimen of 1995 was confirmed microscopically.
The lesion had prominent papillary architecture with mild
to moderate nuclear atypia (Figure 2b, 2c). Foci of pseu-
domyxoma extraperitonei were also observed in sections
of the skin. The tumor cells from the next two debulking
specimens showed similar histological features as the first
one with no obvious progression from the original state of
the bland epithelium – no significant increase in theWorld Journal of Surgical Oncology 2006, 4:60 http://www.wjso.com/content/4/1/60
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degree of atypia, cellular proliferation, increased nuclear
hyperchromasia, abnormal mitoses or the presence of sig-
net ring cells representing a case of DPAM variant of PMP
Case 2 ; 2a. Computed tomographic scan of abdomen show- ing pseudomyxoma peritonei with multiple peritoneal masses  (arrow) with "scalloping effect" seen Figure 2
Case 2 ; 2a. Computed tomographic scan of abdomen show-
ing pseudomyxoma peritonei with multiple peritoneal masses 
(arrow) with "scalloping effect" seen. 2b. Prominent papillary 
architectures (arrow) (haematoxylin-eosin, × 10); 2c. Papil-
lary architectures with mild to moderate nuclear atypia 
(arrow) (hematoxylin-eosin, × 20) with no invasion-repre-
senting a case of the DPAM variant of PMP.
Case 1: 1a. Pseudomyxoma peritonei with multilobulated  polypoid gelatinous masses Figure 1
Case 1: 1a. Pseudomyxoma peritonei with multilobulated 
polypoid gelatinous masses, 1b. Subserosal cystic structures 
filled with mucin and lined by single layer of bland epithelium 
(arrow) in the small bowel. (hematoxylin-eosin, × 10); 1c. 
Numerous cell clusters floating in the mucin pools and infil-
trating the submucosa of small bowel (arrow) (haematoxylin-
eosin, × 20)- PMCA variant of PMPWorld Journal of Surgical Oncology 2006, 4:60 http://www.wjso.com/content/4/1/60
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arising from a borderline or low malignant potential
(LMP) mucinous neoplasm of the appendix.
Discussion
Pseudomyxoma peritonei is an indolent disease and pref-
erentially affects women with an average age of 53 years
[4]. It is traditionally believed that most cases of PMP orig-
inate from ovarian tumors. This belief is challenged
recently by increased usage of immunohistochemical
stains and molecular genetic studies, which showed a
large proportion of these tumors to be secondary to
appendiceal tumors in both men and women [5,8-10].
Although we present 2 cases of male PMP, the fact remains
that more women than men suffer from this condition
according to the published literature [4].
As symptoms remain non-specific the disease presents a
great diagnostic challenge to clinicians. Clinical presenta-
tion is late and patients usually experience a long course
of health deterioration before an accurate diagnosis is
made. Due to its indolent nature, advanced stages of the
disease with generalized peritoneal tumor implants, fis-
tula formation and adhesions are common. In this
advanced stage, abdominal symptoms caused by partial
or complete bowel obstruction are the main complaints.
A precise diagnosis is difficult due to the lack of specific
symptoms in the early stage of the disease. Routine labo-
ratory studies are seldom helpful in making this diagno-
sis. An accurate preoperative diagnosis of pseudomyxoma
peritonei can be aided by radiological imaging with com-
puted tomography if the characteristic "scalloping effect"
on the surface of the visceral organs resulting from com-
pression by the viscous mucinous secretions and the
organizing fibrosis is seen as observed in figure 2a. [1].
The role of magnetic resonance imaging as a diagnostic
tool is unclear. In the majority of cases, it is often an unex-
pected finding at explorative laparoscopy, which remains
the main diagnostic tool with the final diagnosis being
confirmed by histopathology.
Mucinous neoplasms of the appendix are uncommon
entities associated with a variety of underlying pathologi-
cal processes ranging from simple appendiceal mucoceles
to mucinous hyperplasia (hyperplastic polyp), serrated
adenoma, mucinous adenoma/cystadenoma, mucinous
neoplasm of uncertain malignant potential, mucinous
neoplasm of low malignant potential and mucinous cys-
tadenocarcinoma. [11] The exact relationship of these
lesions to PMP is still not clear though many cases of PMP,
predominantly the DPAM variant, are associated with
mucinous neoplasms of the appendix with low malignant
potential (M-LMP) as in case 2. The PMCA variant of PMP
seems to have a higher association with mucinous adeno-
carcinomas of the appendix and other rarer gastrointesti-
nal sites. The pathological features of a borderline or low
malignant potential appendiceal mucinous neoplasm
consists of glands lined by mucinous epithelium with
small basally located nuclei and inconspicuous nucleoli
in a mucinous background as in a mucinous adenoma.
The key associated finding is the presence of epithelium
outside the appendix in association with the mucin and
the peritoneal implants as observed in Case 2. A cystic
ovarian tumor should always be excluded in women with
an appendiceal mucinous neoplasm. The correct diagno-
sis of appendiceal mucinous neoplasm of low malignant
potential (M-LMP) is almost never made pre-operatively
and is suspected intraoperatively in about a third of the
cases. These cases often have a long protracted clinical
course with death occurring decades after the initial diag-
nosis. Death may also occur in the interim period due to
unrelated causes as in our indexed Case 2. Death directly
related to PMP in these cases is due to extensive peritoneal
fibrosis with bowel obstruction and not as result of lymph
node, liver or lung metastases. Appendiceal mucinous cys-
tadenocarcinoma however, should demonstrate overt
cytoarchitectural features of carcinoma including cell clus-
ters with significant cytological atypia, stratification, pap-
illary formation with invasion of the bowel wall. These
cases are associated with an aggressive clinical course
often with liver, lung and lymph node metastatic disease.
[11].
PMP on the other hand can be associated with a mucinous
neoplasm either in the ovary or in the appendix that dem-
onstrate fairly bland well differentiated mucinous epithe-
lium with minimal nuclear features of malignancy, which
further confirms that the origins and nature of the parent
tumors may be variable and that the cytological features
are not always concordant with those of PMP further add-
ing difficulty in determining its biological behavior and
its subtype. Thus the natural history of this disease
remains largely poorly defined.
Recent studies reveal that PMP is a neoplastic disease of
MUC2-expressing goblet cells. Mucinous tumors of the
appendix also express MUC2, which supports an appendi-
ceal rather than an ovarian origin for PMP. This helps to
distinguish PMP secondary involvement of the ovary by
PMP from a primary appendiceal mucinous tumor with
peritoneal implants [12]. The exact origin and mechanism
of this abundant mucin production has been recently
extensively studied. It is believed that PMP is character-
ized by the production of MUC2, a gel forming mucin
that forms strong bonds with the surrounding stroma and
is also believed to have tumor suppressor activities [12].
The extracellular accumulation of mucin is attributed to
an alteration in cell polarity resulting in the glycoproteins
being secreted predominantly in the stroma facing sur-
faces of the tumor cells in contrast to adenocarcinomasWorld Journal of Surgical Oncology 2006, 4:60 http://www.wjso.com/content/4/1/60
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wherein the glycoproteins are secreted either into the
luminal surface or dispersed within the cytoplasm [13].
The evolution of treatment strategies of PMP still remains
debated though the current mainstay of the treatment
remains surgical extirpation of the lesion. Repeated
cytoreductive surgical debulking procedures including
resections of the tumor implants, omentum and obstruc-
tive bowel are common due to recurrence of the disease.
Intra-peritoneal chemotherapy (5FU, Mitomycin C) has
minimal benefit with reduction in the number of foci of
atypical epithelium and or atrophy and degeneration of
the atypical neoplastic epithelium. Based on the Sugar-
baker peritonectomy procedure [14] a study by Draco et al
showed that cytoreductive surgery with intraperitoneal
hyperthermic perfusion permitted complete tumor
removal, and this study confirmed the efficacy of this
combined treatment in terms of improved long-term sur-
vival and better local control of the disease [15]. Indeed,
the current strategy of treatment includes cytoreductive
surgery combined with intraoperative hyperthermic intra-
peritoneal chemotherapy (mitomycin at 42 degrees C).
The aim is to avoid entrapment of tumor cells at operative
sites and to destroy small residual mucinous tumor nod-
ules. This is a combined treatment with a high toxicity,
particularly surgically related [16], but is associated with
long term survival compared to the traditional historical
treatment [17]. As endorsed by Sugarbaker, this new com-
bined treatment should be regarded as the standard of
care for epithelial appendiceal neoplasms and pseu-
domyxoma peritonei syndrome [18] which is best admin-
istered in an established peritoneal carcinomatosis
treatment centre.
Prognosis in this disease is closely related to the bulk of
the disease as evaluated by the tumor site, preoperative
tumor volume and completeness of tumor removal by
cytoreductive surgery and the microscopic degree of differ-
entiation of the neoplastic epithelium as evaluated by the
histopathological examination [17-20]. In this context,
PMP patients with pre-operative elevated tumor markers
such as CEA (carcino-embryonic antigen) and CA 19-9 are
at increased risk of developing recurrent disease despite
aggressive therapy. Likewise, PMP patients with normal
levels of these tumor markers have an overall improved
prognosis [21,22].
Conclusion
We have described two male patients who developed
pseudomyxoma peritonei arising from appendiceal
tumors with a latent period of 23 years in one case. They
both were diagnostically challenging and were accurately
recognized at surgery for bowel obstruction and con-
firmed by histopathology. They represent the two variants
of PMP – the malignant variant of PMCA and the benign
DPAM with well-differentiated tumor who despite tumor
recurrences died of an unrelated event. The former is
treated aggressively with cytoreductive surgery and chem-
otherapy while the latter is principally managed by surgi-
cal debulking procedures. Awareness of this indolent and
rare condition is an important prerequisite for early diag-
nosis and appropriate management. Further, clinical
awareness and recognition of PMP as a potential delayed
consequence years later to an appendiceal lesion should
alert all surgeons to be extremely vigilant while treating
mucinous neoplasms of the appendix, with special care
being directed towards adequate excision and thorough
debridement at the initial diagnosis.
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